Lauren Varney

Ms. Lauren Varney

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LVLauren Varney
Lauren Varney
SMStephen Murtough
Stephen Murtough
MCMarius Cotic
Marius Cotic
RARosemary Abidoph
Rosemary Abidoph
LCLian Chan
Lian Chan
EBElvira Bramon
Elvira Bramon
Background/Objectives: Antipsychotic treatment response varies considerably between individuals, with one potential reason being genetic variation affecting the cytochrome P450 enzymes that metabolise them. Methods: With a diverse sample of 453 participants, we studied the influence of CYP1A2, CYP2D6, and CYP3A4 variation on three antipsychotic treatment outcomes: participant-reported adverse antipsychotic drug reactions, health-related quality of life, and the dose of antipsychotic medication prescribed. These measures were taken from the baseline assessment, before a pharmacogenetic intervention was delivered. Results: Over half of our sample (62.9%) were carriers of an allele associated with altered metabolism of antipsychotic medications on CYP2D6 or CYP3A4, the two genes with pharmacogenetic guidelines for antipsychotic medications. Ultrarapid CYP2D6 metabolisers reported significantly lower levels of adverse antipsychotic drug reactions than normal CYP2D6 metabolisers (mean difference: −11.1; 95% confidence interval [CI]: −18.9, −3.3; p = 0.00575). There was also suggestive evidence of lower quality of life scores in those carrying one (mean difference: −0.0863; 95% CI: −0.1806, 0.0081; p = 0.0731) or two copies (mean difference: −0.0803; 95% CI: −0.1734, 0.0129; p = 0.0914) of the CYP1A2*30-inducible allele. Conclusions: Our findings suggest that even when looking at a small number of cytochrome P450 genes, carrying an allele associated with altered antipsychotic medication metabolism is relatively common. We also found evidence that the CYP genotype can influence antipsychotic treatment outcomes, specifically adverse drug reactions and quality of life scores.

16 December 2024 in Wellcome Open Research
Verified
Journal Article
Open access
SMStephen Murtough
Stephen Murtough
DPDaniele Panconesi
Daniele Panconesi
CLChen Lu
Chen Lu
RARosemary Abidoph
Rosemary Abidoph
MCMarius Cotic
Marius Cotic
EBElvira Bramon
Elvira Bramon
Background Hearing loss is a risk factor for developing auditory hallucinations and other psychosis symptoms. To date, very little research has investigated hearing loss in individuals with a high genetic risk of developing schizophrenia and other types of psychosis. 13 copy number variant (CNV) loci are robustly associated with an increased risk of schizophrenia. Of these, microdeletions at 22q11.2 often lead to some hearing loss, and mouse models of this CNV display impaired auditory functioning. We hypothesise that individuals who have a high genetic risk of schizophrenia may also experience hearing problems. This scoping review will explore whether the 13 schizophrenia-associated CNVs are related to hearing problems, including peripheral hearing loss and other auditory problems, in humans and related mouse models. Methods Our scoping review will follow guidelines provided by the Joanna Briggs Institute and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. A systematic search will be completed using PubMed (MEDLINE), Embase, PsychINFO, and Cochrane Library databases, as well as other sources to identify relevant grey literature. Search terms will include all commonly used synonyms for hearing loss and problems with auditory perception, and both human and mouse studies that describe relevant CNVs will be included. Search lists will be screened by two authors independently, according to eligibility criteria, and data will be extracted and summarised using a narrative approach. Conclusions To our knowledge, this will be the first scoping review to explore auditory functioning across all CNVs that confer high schizophrenia risk. Looking ahead, if hearing problems are a clinical feature in these groups (including humans and related mouse models), they may serve as useful genetic models for future mechanistic studies.

10 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
LVLauren Varney
Lauren Varney
KJKrisztina Jedlovszky
Krisztina Jedlovszky
BWBaihan Wang
Baihan Wang
SMStephen Murtough
Stephen Murtough
MCMarius Cotic
Marius Cotic
GRGenetic Risk
Genetic Risk
Background Up to 80% of psychosis patients experience cognitive impairment. High heritability of both psychosis and cognition means cognitive performance could be an endophenotype for psychosis. Methods Using samples of adults (N=4,506) and children (N=10,981), we investigated the effect of polygenic scores (PGSs) for schizophrenia and bipolar disorder on cognitive performance, and PGSs for intelligence and educational attainment on psychosis symptoms. Results Schizophrenia PGS was negatively associated with visuospatial processing/problem-solving in the adult sample (beta: −0.0569; 95% confidence interval [CI]: −0.0926, −0.0212) and working memory (beta: −0.0432; 95% CI: −0.0697, −0.0168), processing speed (b: −0.0491; 95% CI: −0.0760, −0.0223), episodic memory (betas: −0.0581 to −0.0430; 95% CIs: −0.0847 to −0.0162), executive functioning (beta: −0.0423; 95% CI: −0.0692, −0.0155), fluid intelligence (beta: −0.0583; 95% CI: −0.0847, −0.0320), and total intelligence (beta: −0.0458; 95% CI: −0.0709, −0.0206) in the child sample. Bipolar disorder PGS was not associated with any cognitive endophenotypes studied. Lower values on the PGS for intelligence were associated with higher odds of psychosis in adults (odds ratio [OR]: 0.886; 95% CI: 0.811– 0.968) and psychotic-like experiences in children (OR: 0.829; 95% CI: 0.777–0.884). In children, a lower polygenic score for educational attainment was associated with greater odds of psychotic-like experiences (OR: 0.771; 95% CI: 0.724–0.821). Conclusions The relationship between psychosis and cognitive impairment can be demonstrated bidirectionally at the neurobiological level. The effect of schizophrenia PGS on cognitive performance differs across the lifespan and cognitive domains. Specific cognitive domains may therefore be better endophenotypes than overall cognition.

21 November 2025 in Translational Psychiatry
Verified
Journal Article
Open access
LVLauren Varney
Lauren Varney
KJKrisztina Jedlovszky
Krisztina Jedlovszky
BWBaihan Wang
Baihan Wang
SMStephen Murtough
Stephen Murtough
MCMarius Cotic
Marius Cotic
EBElvira Bramon
Elvira Bramon
Cognitive impairment is an important but often under-researched symptom in psychosis. Both psychosis and cognition are highly heritable and there is evidence of a genetic effect on the relationship between them. Using samples of adults ( N = 4 506) and children ( N = 10 981), we investigated the effect of schizophrenia and bipolar disorder polygenic scores on cognitive performance, and intelligence and educational attainment polygenic scores on psychosis presentation. Schizophrenia polygenic score was negatively associated with visuospatial processing in adults (beta: −0.0569; 95% confidence interval [CI]: −0.0926, −0.0212) and working memory (beta: −0.0432; 95% CI: −0.0697, −0.0168), processing speed (beta: −0.0491; 95% CI: −0.0760, −0.0223), episodic memory (betas: −0.0581 to −0.0430; 95% CIs: −0.0847, −0.0162), executive functioning (beta: −0.0423; 95% CI: −0.0692, −0.0155), fluid intelligence (beta: −0.0583; 95% CI: −0.0847, −0.0320), and total intelligence (beta: −0.0458; 95% CI: −0.0709, −0.0206) in children. Bipolar disorder polygenic score was not associated with any cognitive domains studied. Lower polygenic scores for intelligence were associated with greater odds of psychosis in adults (odds ratio [OR]: 0.886; 95% CI: 0.811–0.968). In children, lower polygenic scores for both intelligence (OR: 0.829; 95% CI: 0.777–0.884) and educational attainment (OR: 0.771; 95% CI: 0.724–0.821) were associated with greater odds of psychotic-like experiences. Our findings suggest that polygenic scores for both cognitive phenotypes and psychosis phenotypes are implicated in the relationship between psychosis and cognitive performance. Further research is needed to determine the direction of this effect and the mechanisms by which it occurs.

24 September 2024 in Wellcome Open Research
Verified
Journal Article
Open access
SMStephen Murtough
Stephen Murtough
DPDaniele Panconesi
Daniele Panconesi
CLChen Lu
Chen Lu
RARosemary Abidoph
Rosemary Abidoph
MCMarius Cotic
Marius Cotic
EBElvira Bramon
Elvira Bramon
Background Hearing loss is a risk factor for developing auditory hallucinations and other psychosis symptoms. To date, very little research has investigated hearing loss in individuals with a high genetic risk of developing schizophrenia and other types of psychosis. 13 copy number variant (CNV) loci are robustly associated with an increased risk of schizophrenia. Of these, microdeletions at 22q11.2 often lead to some hearing loss, and mouse models of this CNV display impaired auditory functioning. We hypothesise that hearing impairment is an understudied mechanism that contributes to the formation of psychosis symptoms in individuals at high genetic risk. This scoping review will explore whether the 13 schizophrenia-associated CNVs are related to hearing problems, including peripheral hearing loss and other auditory problems, in humans and related mouse models. Methods Our scoping review will follow guidelines provided by the Joanna Briggs Institute and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews. A systematic search will be completed using PubMed (MEDLINE), Embase, PsychINFO, and Cochrane Library databases, as well as other sources to identify relevant grey literature. Search terms will include all commonly used synonyms for hearing loss and problems with auditory perception, and both human and mouse studies that describe relevant CNVs will be included. Search lists will be screened by two authors independently, according to eligibility criteria, and data will be extracted and summarised using a narrative approach, and meta-analysis methods will be used if possible. Conclusions To our knowledge, this will be the first scoping review to explore auditory functioning across all CNVs that confer high schizophrenia risk. Looking ahead, if hearing problems are a clinical feature in these groups (including humans and related mouse models), they may serve as useful genetic models for future mechanistic studies.